Limits...
Dopaminergic therapy in Parkinson's disease decreases cortical beta band coherence in the resting state and increases cortical beta band power during executive control.

George JS, Strunk J, Mak-McCully R, Houser M, Poizner H, Aron AR - Neuroimage Clin (2013)

Bottom Line: Dopaminergic medication reduced this coherence.Off medication increased beta band power over right frontal cortex for successful stopping and over bilateral sensorimotor cortex for going, especially for those patients who showed greater clinical improvement.Thus, medication reduced pathological coherence in beta band at rest and increased task related beta power for two potentially dissociable cortico-basal ganglia circuits.

View Article: PubMed Central - PubMed

Affiliation: Department of Psychology, University of California San Diego, USA.

ABSTRACT
It is not yet well understood how dopaminergic therapy improves cognitive and motor function in Parkinson's disease (PD). One possibility is that it reduces the pathological synchronization within and between the cortex and basal ganglia, thus improving neural communication. We tested this hypothesis by recording scalp electroencephalography (EEG) in PD patients when On and Off medication, during a brief resting state epoch (no task), and during performance of a stop signal task that is thought to engage two partially overlapping (or different) frontal-basal-ganglia circuits. For resting state EEG, we measured pair-wise coherence between scalp electrodes in several frequency bands. Consistent with previous studies, in the Off medication state, those patients with the greatest clinical impairment had the strongest coherence, especially in the beta band, indicating pathological over-synchronization. Dopaminergic medication reduced this coherence. For the stop signal task, On vs. Off medication increased beta band power over right frontal cortex for successful stopping and over bilateral sensorimotor cortex for going, especially for those patients who showed greater clinical improvement. Thus, medication reduced pathological coherence in beta band at rest and increased task related beta power for two potentially dissociable cortico-basal ganglia circuits. These results support the hypothesis that dopaminergic medication in PD improves neural communication both at rest and for executive and motor function.

No MeSH data available.


Related in: MedlinePlus

Dopaminergic medication does not modulate mean power in PD patients. Mean power estimates (Pxx) in delta, theta, alpha, beta and gamma bands across the 32 channel locations for control subjects, patients On and Off medication. An analysis using 2-way ANOVA of all groups and frequency bands was performed at each electrode. A main effect of group was observed at PO3, O2, PO4 and P4 (F2,4 = 18.20, 16.81, 14.01, 17.90 all P < 0.05). Further analysis at these electrodes was performed using paired and unpaired sample t-tests for each frequency band. In the theta band, On had more theta compared to controls at PO3, O2, PO4 and P4 t30 = 2.16, 2.41, 2.21, 2.38 all P < 0.05; Off had more theta compared to controls at PO3 and O2 t30 = 2.05, 2.21, all P < 0.05. Medication related changes in each frequency band were studied using a repeated measures ANOVA with two within subject factors, medication (On/Off) and channel (32 channels). There was no main effect of medication in any frequency band (delta F1,31 = 0.33, P = 0.57; theta F1,31 = 0.72, P = 0.41; alpha F1,31 = 0.10, P = 0.74; beta F1,31 = 0.002, P = 0.96; gamma F1,31 = 0.18, P = 0.67).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3814961&req=5

f0035: Dopaminergic medication does not modulate mean power in PD patients. Mean power estimates (Pxx) in delta, theta, alpha, beta and gamma bands across the 32 channel locations for control subjects, patients On and Off medication. An analysis using 2-way ANOVA of all groups and frequency bands was performed at each electrode. A main effect of group was observed at PO3, O2, PO4 and P4 (F2,4 = 18.20, 16.81, 14.01, 17.90 all P < 0.05). Further analysis at these electrodes was performed using paired and unpaired sample t-tests for each frequency band. In the theta band, On had more theta compared to controls at PO3, O2, PO4 and P4 t30 = 2.16, 2.41, 2.21, 2.38 all P < 0.05; Off had more theta compared to controls at PO3 and O2 t30 = 2.05, 2.21, all P < 0.05. Medication related changes in each frequency band were studied using a repeated measures ANOVA with two within subject factors, medication (On/Off) and channel (32 channels). There was no main effect of medication in any frequency band (delta F1,31 = 0.33, P = 0.57; theta F1,31 = 0.72, P = 0.41; alpha F1,31 = 0.10, P = 0.74; beta F1,31 = 0.002, P = 0.96; gamma F1,31 = 0.18, P = 0.67).


Dopaminergic therapy in Parkinson's disease decreases cortical beta band coherence in the resting state and increases cortical beta band power during executive control.

George JS, Strunk J, Mak-McCully R, Houser M, Poizner H, Aron AR - Neuroimage Clin (2013)

Dopaminergic medication does not modulate mean power in PD patients. Mean power estimates (Pxx) in delta, theta, alpha, beta and gamma bands across the 32 channel locations for control subjects, patients On and Off medication. An analysis using 2-way ANOVA of all groups and frequency bands was performed at each electrode. A main effect of group was observed at PO3, O2, PO4 and P4 (F2,4 = 18.20, 16.81, 14.01, 17.90 all P < 0.05). Further analysis at these electrodes was performed using paired and unpaired sample t-tests for each frequency band. In the theta band, On had more theta compared to controls at PO3, O2, PO4 and P4 t30 = 2.16, 2.41, 2.21, 2.38 all P < 0.05; Off had more theta compared to controls at PO3 and O2 t30 = 2.05, 2.21, all P < 0.05. Medication related changes in each frequency band were studied using a repeated measures ANOVA with two within subject factors, medication (On/Off) and channel (32 channels). There was no main effect of medication in any frequency band (delta F1,31 = 0.33, P = 0.57; theta F1,31 = 0.72, P = 0.41; alpha F1,31 = 0.10, P = 0.74; beta F1,31 = 0.002, P = 0.96; gamma F1,31 = 0.18, P = 0.67).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3814961&req=5

f0035: Dopaminergic medication does not modulate mean power in PD patients. Mean power estimates (Pxx) in delta, theta, alpha, beta and gamma bands across the 32 channel locations for control subjects, patients On and Off medication. An analysis using 2-way ANOVA of all groups and frequency bands was performed at each electrode. A main effect of group was observed at PO3, O2, PO4 and P4 (F2,4 = 18.20, 16.81, 14.01, 17.90 all P < 0.05). Further analysis at these electrodes was performed using paired and unpaired sample t-tests for each frequency band. In the theta band, On had more theta compared to controls at PO3, O2, PO4 and P4 t30 = 2.16, 2.41, 2.21, 2.38 all P < 0.05; Off had more theta compared to controls at PO3 and O2 t30 = 2.05, 2.21, all P < 0.05. Medication related changes in each frequency band were studied using a repeated measures ANOVA with two within subject factors, medication (On/Off) and channel (32 channels). There was no main effect of medication in any frequency band (delta F1,31 = 0.33, P = 0.57; theta F1,31 = 0.72, P = 0.41; alpha F1,31 = 0.10, P = 0.74; beta F1,31 = 0.002, P = 0.96; gamma F1,31 = 0.18, P = 0.67).
Bottom Line: Dopaminergic medication reduced this coherence.Off medication increased beta band power over right frontal cortex for successful stopping and over bilateral sensorimotor cortex for going, especially for those patients who showed greater clinical improvement.Thus, medication reduced pathological coherence in beta band at rest and increased task related beta power for two potentially dissociable cortico-basal ganglia circuits.

View Article: PubMed Central - PubMed

Affiliation: Department of Psychology, University of California San Diego, USA.

ABSTRACT
It is not yet well understood how dopaminergic therapy improves cognitive and motor function in Parkinson's disease (PD). One possibility is that it reduces the pathological synchronization within and between the cortex and basal ganglia, thus improving neural communication. We tested this hypothesis by recording scalp electroencephalography (EEG) in PD patients when On and Off medication, during a brief resting state epoch (no task), and during performance of a stop signal task that is thought to engage two partially overlapping (or different) frontal-basal-ganglia circuits. For resting state EEG, we measured pair-wise coherence between scalp electrodes in several frequency bands. Consistent with previous studies, in the Off medication state, those patients with the greatest clinical impairment had the strongest coherence, especially in the beta band, indicating pathological over-synchronization. Dopaminergic medication reduced this coherence. For the stop signal task, On vs. Off medication increased beta band power over right frontal cortex for successful stopping and over bilateral sensorimotor cortex for going, especially for those patients who showed greater clinical improvement. Thus, medication reduced pathological coherence in beta band at rest and increased task related beta power for two potentially dissociable cortico-basal ganglia circuits. These results support the hypothesis that dopaminergic medication in PD improves neural communication both at rest and for executive and motor function.

No MeSH data available.


Related in: MedlinePlus